Navigation Links
Advanced Life Sciences Announces First Quarter 2008 Financial Results
Date:5/7/2008

ER ASSETS:

Other assets 18,750 10,000

Total other assets 18,750 10,000

TOTAL ASSETS $13,398,035 $19,911,542

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $1,458,912 $2,685,751

Accrued clinical trial expenses 754,402 2,776,543

Other accrued expenses 463,347 330,441

Accrued interest payable 21,070 22,756

Short-term lease payable 7,538 7,259

Short-term notes payable - related party 2,000,000 -

Total current liabilities 4,705,269 5,822,750

Long-term lease payable 10,824 12,818

Long-term grant payable 500,000 500,000

Long-term notes payable - related party - 2,000,000

Notes payable 3,915,000 3,915,000

Total liabilities 9,131,093 12,250,568

COMMITMENTS AND CONTINGENCIES

MINORITY INTEREST - -

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value-60,000,000

shares authorized; 38,502,987 issued and

outstanding at March 31, 2008; 38,502,987

shares issued and outstanding at December 31,

2007 385,030 385,030

Additional paid-in capital 107,007,634 106,859,532

Deficit accumulated during the

development stage (103,125,722) (99,583,588)

Total stockholders' equity 4,266,942 7,660,974

TOTAL LIABILITIES AND STOCKHOLDE
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
5. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
6. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
7. Advanced Life Sciences Receives Nasdaq Notification
8. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
11. Advanced Medical Specialties Joins US Oncology Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Lisa Kulik saw fireworks for the first time in ... a groundbreaking retinal implant co-invented by Mark Humayun ... University of Southern California (USC) Eye Institute. ... resident who has retinitis pigmentosa, a degenerative disease ... 2, she became the first person west of the ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... 2014 After the boom of the ... next beverage craze is going to be the stress ... can use Stress Relief energy pattern which can be ... of a beverage, including minerals, herbs and liquids. Stress ... that power into rapid recovery and helping to adapt ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... 28 N30 Pharma (N30), a,biopharmaceutical company focused ... regulate nitric oxide bioavailability,announced today that it has ... N30 will use proceeds from this financing ... expand its discovery and preclinical,research in the area ...
... Be Webcast Live On Company,s Website -, TUSTIN, ... ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ... that senior management will,present at the BIO Investor Forum ... (6:45 pm EDT). The conference will be held at ...
... ITMN ) announced today that it will release ... at 4:00 p.m. Eastern time.,A live conference call and ... time that same day., To access the live ... To access the,webcast, please log on to the company,s ...
Cached Biology Technology:N30 Pharma Announces Financing, Expansion of Board 2Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2InterMune to Release Third Quarter 2008 Financial Results on November 6 2
(Date:8/27/2014)... (June, 2014) Outstanding basic research, a growing ... dedication to patient care have earned the Herbert ... Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 ... National Cancer Institute (NCI). The grant renews the ... Comprehensive Cancer Centers in New York City and ...
(Date:8/27/2014)... factors thought to be associated with outcomes after ... age of the patient, mechanism of injury, nerve ... method, operation technique, and repair materials. However, despite ... peripheral nerve injuries, there is no agreement regarding ... the dose-effect relationship of the predictors has not ...
(Date:8/27/2014)... research finds , Gamblers show the same tendencies ... has shown. , Researchers, led by Dr Elliot Ludvig ... tests that found that both human gamblers and pigeons ... low-value rewards. , Published in Biology Letters , ... important role that memories of previous biggest wins and ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Gamblers are greedy bird-brains, University of Warwick research finds 2
... the body's motor nerve cells grow along proper paths ... inhibiting spinal-cord neurons from regenerating after injury, researchers at ... the researchers found that a component of myelin ?a ... in adult vertebrates ?chemically blocks the ability of nerve ...
... for the first time that bacteria, in addition to ... sparkling wine known as Cava. They report their findings ... Society for Microbiology. , "Bacteria found in Cava samples ... in terms of aroma, flavor, bubble size and bubble ...
... hanging basket style device is at the heart of a plan ... sex drive of a major pest of fruit ... that very same pest. The device allows growers to selectively ... killing other beneficial insects. , The researchers at Warwick HRI, the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3After the yeast is gone bacteria continue to develop flavor of sparkling wine 2Hanging baskets of sex and death help fruit growers 2
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Biology Products: